NantHealth saw its stock price close down 23 percent on Monday, on the heels of a report from STAT showing how Dr. Patrick Soon-Shiong used philanthropy to boost his health technology company.

As investors soured on the stock, a health care analyst defended the company and a law firm put out a call for participants in a potential class action investor suit.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Wouldn’t surprise me to see NantHealth’s lawyers to come after STATnews (even if just a sort of SLAPP reprisal action). Hope the article was fully legally vetted prior to publication.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy